Search

Quinupristin

Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. … The combination of the two components acts synergistically and is more effective in vitro than each component alone.

Dimenhydrinate

effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory

Nevirapine

Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Lipegfilgrastim

It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia. … Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity

Eptinezumab

[L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). … [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

Chloroxine

Chloroxine is a compound used in some shampoos for the treatment of dandruff and seborrheic dermatitis of the scalp.

Sodium ascorbate

Donislecel

[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control … [L47196] Donislecel is particularly beneficial for type 1 diabetic patients with hypoglycemia unawareness, the inability to detect blood glucose dropping and thus unable to prevent further hypoglycemia

Azacitidine

In January 2007, the FDA approved the intravenous administration of azacitidine. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]

Trilaciclib

Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.